Andersen MH - Search Results

1

The immunogenicity of the hTERT540-548 peptide in cancer.

Wenandy L, Sørensen RB, Sengeløv L, Svane IM, thor Straten P, Andersen MH. Wenandy L, et al. Among authors: andersen mh. Clin Cancer Res. 2008 Jan 1;14(1):4-7. doi: 10.1158/1078-0432.CCR-07-4590. Clin Cancer Res. 2008. PMID: 18172245 Review.

2

Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients.

Schrama D, Andersen MH, Terheyden P, Schrøder L, Pedersen LO, thor Straten P, Becker JC. Schrama D, et al. Among authors: andersen mh. Cancer Res. 2001 Jan 15;61(2):493-6. Cancer Res. 2001. PMID: 11212239

3

Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.

Andersen MH, Pedersen LO, Becker JC, Straten PT. Andersen MH, et al. Cancer Res. 2001 Feb 1;61(3):869-72. Cancer Res. 2001. PMID: 11221872

4

In situ cytokine therapy: redistribution of clonally expanded T cells.

thor Straten P, Guldberg P, Schrama D, Andersen MH, Moerch U, Seremet T, Siedel C, Reisfeld RA, Becker JC. thor Straten P, et al. Among authors: andersen mh. Eur J Immunol. 2001 Jan;31(1):250-8. doi: 10.1002/1521-4141(200101)31:1<250::AID-IMMU250>3.0.CO;2-8. Eur J Immunol. 2001. PMID: 11265641 Free article.

5

Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.

Andersen MH, Pedersen LO, Capeller B, Bröcker EB, Becker JC, thor Straten P. Andersen MH, et al. Cancer Res. 2001 Aug 15;61(16):5964-8. Cancer Res. 2001. PMID: 11507035

6

Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: a case report.

Pedersen LØ, Vetter CS, Mingari MC, Andersen MH, thor Straten P, Bröcker EB, Becker JC. Pedersen LØ, et al. Among authors: andersen mh. J Invest Dermatol. 2002 Apr;118(4):595-9. doi: 10.1046/j.1523-1747.2002.01698.x. J Invest Dermatol. 2002. PMID: 11918704 Free article.

7

Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression.

Terheyden P, Schrama D, Pedersen LØ, Andersen MH, Kämpgen E, thor Straten P, Becker JC. Terheyden P, et al. Among authors: andersen mh. Scand J Immunol. 2003 Nov;58(5):566-71. doi: 10.1046/j.1365-3083.2003.01324.x. Scand J Immunol. 2003. PMID: 14629628 Free article.

8

HLA-B35-restricted immune responses against survivin in cancer patients.

Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. Reker S, et al. Among authors: andersen mh. Int J Cancer. 2004 Mar 1;108(6):937-41. doi: 10.1002/ijc.11634. Int J Cancer. 2004. PMID: 14712500 Free article.

9

Identification of novel survivin-derived CTL epitopes.

Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersen MH. Reker S, et al. Among authors: andersen mh. Cancer Biol Ther. 2004 Feb;3(2):173-9. doi: 10.4161/cbt.3.2.611. Epub 2004 Feb 1. Cancer Biol Ther. 2004. PMID: 14726703

10

Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.

Andersen MH, Gehl J, Reker S, Pedersen LØ, Becker JC, Geertsen P, thor Straten P. Andersen MH, et al. Semin Cancer Biol. 2003 Dec;13(6):449-59. doi: 10.1016/j.semcancer.2003.09.009. Semin Cancer Biol. 2003. PMID: 15001164 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

379 results

Search Page